Wilson's disease (WD) is an inherited metabolic disorder related to disturbances of copper metabolism, and predominantly presents with liver and neuropsychiatric symptoms. In most cases it can be successfully treated with anti-copper agents, and both liver function and neuropsychiatric symptoms typically improve. Treatment guidelines for WD include recommendations for anti-copper treatment as well as for the treatment of liver failure symptoms. Recently, recommendations for treatment of the neurological symptoms of WD have also been proposed. Although most WD patients present with psychiatric symptoms at some stage of the disease, currently there are no guidelines for the treatment of the psychiatric manifestations. Treatment of the psychiatric symptoms of WD is often guided by general psychiatric experience, which typically glosses over the specificity of WD, and can result in severe neurological and/or hepatic complications. Here we review and discuss the possible treatments available for the mood disturbances, psychosis, behavioral and cognitive disorders that can occur in WD, as well as their efficacy.

2nd Department of Neurology Institute of Psychiatry and Neurology Sobieskiego 9 02 957 Warsaw Polandc

2nd Department of Neurology Institute Psychiatry and Neurology Warsaw Poland

Department of Adult Psychiatry Poznan University of Medical Sciences Poznan Poland

Department of Neurology and Centre of Clinical Neuroscience 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Specialist Medical Practice Tomasz Szafrański Warsaw Poland

Zobrazit více v PubMed

European Association for the Study of the Liver Disease. EASL clinical practice guidelines: Wilson’s disease. J Hepatol 2012; 56: 671–685. PubMed

Dusek P, Litwin T, Czlonkowska A. Wilson disease and other neurodegenerations with metal accumulations. Neurol Clin 2015; 33: 175–204. PubMed

Wilson SA. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34: 20–509. PubMed

Czlonkowska A, Tarnacka B, Litwin T, et al. Wilson’s disease: cause of mortality in 164 patients during 1992–2003 observation period. J Neurol 2005; 252: 698–703. PubMed

Bruha R, Marecek Z, Pospilova L, et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int 2011; 31: 83–91. PubMed

Beinhardt S, Leiss W, Stattermayer AF, et al. Long term outcomes of patients with Wilson disease in large Austrian cohort. Clin Gastroenetrol Hepatol 2014; 12: 683–689. PubMed

Denning TR. Psychiatric aspects of Wilson’s disease. Br J Psychiatry 1985; 147: 677–682. PubMed

Denning TR, Berrios G. Wilson’s disease psychiatric symptoms in 195 cases. Arch Gen Psychiatry 1989; 46: 1126–1134. PubMed

Akil M, Brewer GJ. Psychiatric and behavioral abnormalities in Wilson’s disease. Adv Neurol 1995; 65: 171–178. PubMed

Carta MG, Mura G, Sorbello O, et al. Quality of life in psychiatric symptoms in Wilson’s disease: the relevance of bipolar disorders. Clin Pract Epidemiol Ment Health 2012; 8: 102–109. PubMed PMC

Aggarval A, Bhatt M. The pragmatic treatment of Wilson’s disease. Mov Disord Clin Pract 2014; 1: 14–23. PubMed PMC

Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilson’s disease: a review. Gen Hosp Psychiatry 2014; 36: 53–62. PubMed

Litwin T, Dzieżyc K, Karliński M, et al. Psychiatric disturbances as a first clinical symptom of Wilson’s disease. Psychiatr Pol 2016; 50: 337–344. PubMed

Mura G, Zimbrean PC, Demelia L, et al. Psychiatric comorbidity in Wilson’s disease. Int Rev Psychiatry 2017; 29: 445–462. PubMed

Zimbrean PC, Schilsky ML. The spectrum of psychiatric symptoms in Wilson’s disease: treatment and prognostic considerations. Am J Psychiatry 2015; 172: 1068–1072. PubMed

Ring HA, Serra-Mestres J. Neuropsychiatry of the basal ganglia. J Neurol Neurosurg Psychiatry 2002; 72: 12–21. PubMed PMC

Aman MG, De Smedt G, Derivan A, et al. ; Risperidone Disruptive Behavior Study Group. Double-blind, placebo controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337–1346. PubMed

Groves M, van Dujin E, Anderson K, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington’s disease. PLoS Curr 2011; 3: RRN1259. PubMed PMC

Fereira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol 2013; 20: 5–15. PubMed

Bloise MC, Berardelli I, Roseli V, et al. Psychiatric disturbances in patients with progressive supranuclear palsy: a case control study. Parkinsonism Relat Disord 2014; 20: 965–968. PubMed

Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson’s disease. Neurotherapeutics 2014; 11: 78–91. PubMed PMC

Grover S, Somaiya M, Kumar S, et al. Psychiatric aspects of Parkinson’s disease. J Neurosci Rural Pract 2015; 6: 65–76. PubMed PMC

Pena E, Mata M, Lopez-Manzanares L, et al. Antidepressants in Parkinson’s disease: recommendations by the movement disorder study group of the Neurological Association of the Madrid. Neurologia. Epub ahead of print 19 March 2016. DOI: 10.1016/j.nrl.2016.02.002. PubMed DOI

Konig P. Psychopathological alterations in cases of symmetrical basal ganglia sclerosis. Biol Psychiatry 1989; 25: 459–468. PubMed

Lafer B, Renshaw PF, Sachs GS. Major depression and the basal ganglia. Psychiatr Clin N Am 1997; 20: 885–896. PubMed

Rosenblatt A, Leroi I. Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics 2000; 41: 24–30. PubMed

Tu J. The inadvisability of neuroleptic medication in Wilson’s disease. Biol Psychiatry 1981; 16: 963–967. PubMed

Kumawat BL, Sharma CM, Triphati G, et al. Wilson’s disease presenting as isolated obsessive-compulsive disorders. Indian J Med Sci 2007; 61: 607–610. PubMed

Gwirtsman HE, Prager J, Henkin R. Case report of anorexia nervosa associated with Wilson’s disease. Int J Eat Disord 1993; 31: 241–244. PubMed

Portala K, Westermark K, Ekselius L, et al. Personality traits in treated Wilson’s disease determined by means of the Karolinska Scales of Personality (KSP). Eur Psychiatry 2001; 16: 362–371. PubMed

Walter G, Lyndon B. Depression in hepatolenticular degeneration (Wilson’s disease). Aust N Z J Psychiatry 1997; 31: 880–882. PubMed

Chand PK, Murthy P. Mania as a presenting symptom of Wilson’s disease. Acta Neuropsychiatr 2006; 18: 47–49. PubMed

Loganathan S, Nayak R, Sinha S, et al. Treating mania in Wilson’s disease with lithium. J Neuropsychiatry Clin Neurosci 2008; 20: 487–489. PubMed

Rybakowski JK, Litwin T, Chlopocka-Wozniak M, et al. Lithium treatment of a bipolar patient with Wilson’s disease: a case report. Pharmacopsychiatry 2013; 46: 120–121. PubMed

Cummings J. Subcortical dementia: neuropsychology, neuropsychiatry and pathophysiology. Br J Psychiatry 1986; 149: 682–697. PubMed

Medalia A, Isaacs-Glaberman K, Scheinberg IH. Neuropsychological impairment in Wilson’s disease. Arch Neurol 1988; 45: 502–504. PubMed

Seniów J, Bak T, Gajda J, et al. Cognitive functioning in neurologically and asymptomatic forms of Wilson’s disease. Mov Disord 2002; 17: 1077–1083. PubMed

Frota NAF, Caramelli P, Barbosa ER. Cognitive impairment in Wilson’s disease. Dement Neuropsychol 2009; 3: 16–21. PubMed PMC

Iwanski S, Seniow J, Lesniak M, et al. Diverse attention deficits in patients with neurologically symptomatic and asymptomatic Wilson’s diseases. Neuropsychology 2015; 29: 25–30. PubMed

Nevsimalova S, Buskova J, Bruha R, et al. Sleep disorders in Wilson’s disease. Eur J Neurol 2011; 18: 184–190. PubMed

Portala K, Westermark K, von Knorring L, et al. Psychopathology in treated Wilson’s disease determined by means of CPRS expert and self-ratings. Acta Psychiatr Scand 2000; 101: 104–109. PubMed

Wichowicz HM, Cubała JW, Slawek J. Wilson’s diseases associated with delusional disorder. Psychiatry Clin Neurosci 2006; 60: 758–760. PubMed

Spyiridi S, Diakogiannis I, Michaelides M, et al. Delusional disorder and alcohol abuse in a patient with Wilson’s disease. Gen Hosp Psychiatr 2008; 6: 585–586. PubMed

Kumar R, Datta S, Jaysellan L, et al. The psychiatric aspects of Wilson’s disease: a study from neurologic unit. Indian J Psychiatry 1996; 38: 208–211. PubMed PMC

Shnmugiah A, Sinha S, Prashanth LK, et al. Psychiatric manifestations in Wilson’s disease: a cross-sectional analysis. J Neuropsychiatry Clin Neursci 2008; 20: 81–85. PubMed

Svetel M, Potrebic A, Pekmezovic T, et al. Neuropsychiatric aspects of treated Wilson’s disease. Parkinsonism Relat Disord 2009; 15: 772–725. PubMed

Scheinberg IH, Sternlieb I. Wilson’s disease. Philadelphia: WB Saunders, 1984.

apps.who.int/classifications/icd10/browse/2010/en—ICD10: version 2010—English World Health Organization.

Castagnini AC, Fusar-Poli P. Diagnostic validity of ICD-10 acute and transient psychotic disorders and DSM-5 brief psychotic disorders. Eur Psychiatry 2017; 45; 104–113. PubMed

Azova S, Rice T, Garcia-Delgar B, et al. New-onset psychosis in an adolescent with Wilson’s disease. J Child Adolesc Psychopharmacol 2016; 26: 301–304. PubMed

Srinivas K, Sinh S, Taly AB, et al. Dominant psychiatric manifestations in Wilson’s disease: diagnostic and therapeutic challenge. J Neurol Sci 2008; 266: 104–108. PubMed

Rodrigues AC, Dalgalarrondo P. Neuropsychiatric disturbances in Wilson’s disease and use of electroconvulsive therapy: case report. Arq Neuropsiquaitr 2003; 61: 876–880. PubMed

Sahoo MK, Avasthi A, Sahoo M, et al. Psychiatric manifestations of Wilson’s disease and treatment with electroconvulsive therapy. Indian J Psychiatry 2010; 52: 66–68. PubMed PMC

Carta MG, Sorbello O, Moro MF, et al. Bipolar disorders and Wilson’s disease. BMC Psychiatry 2012; 12: 52. PubMed PMC

Litwin T, Chabik G, Członkowska A. Acute focal dystonia induced by a tricyclic antidepressant in a patient with Wilson disease: a case report. Neurol Neurochir Pol 2013; 47: 502–506. PubMed

Bleakley S. Identifying and reducing the risk of antipsychotic drug interactions. Prog Neurol Psychiatry 2012; 16: 20–24.

Litwin T, Dzieżyc K, Karliński M, et al. Early neurological worsening in patients with Wilson’s diseases. J Neurol Sci 2015; 355: 162–167. PubMed

Chung YS, Ravi SD, Borge GF. Psychosis in Wilson’s disease. Psychosomatics 1986; 27: 65–66. PubMed

Krim E, Barroso B. Psychiatric disorders treated with clozapine in a patient with Wilson’s disease. Presse Med 2001; 30: 738. PubMed

Jukic I, Titlic M, Tonkic A, et al. Psychosis and Wilson’s disease: a case report. Psychiatr Danub 2006; 18: 105–107. PubMed

Benhamia T, Tirouche YD, Abaoub-Germain A, et al. The onset of psychiatric disorders and Wilson’s disease. Encephale 2007; 33: 924–932. PubMed

Litwin T, Dusek P, Czlonkowska A. Neurological manifestations in Wilson’s disease: possible treatment options for symptoms. Expert Opin on Orphans Drugs 2016; 4: 719–728.

Cox DW. A screening test for Wilson’s disease and its application to psychiatric patients. Can Med Assoc J 1967; 96: 83–86. PubMed PMC

Demily C, Parent F, Cheillan D, et al. Screening of Wilson’s disease in psychiatric population: difficulties and pitfalls. A preliminary study. Ann Gen Psychiatry 2017; 16: 19. PubMed PMC

Kulaksizoglu IB, Polat A. Quetiapine for mania with Wilson’s disease. Psychosomatics 2003; 44: 438–439. PubMed

Basu A, Thanapal S, Sood M, et al. Catatonia: an unusual manifestation of Wilson’s disease. J Neuropsychiatry Clin Neurosci 2015; 27: 72–73. PubMed

Kontaxakis V, Stefanis C, Markidis M, et al. Neuroleptic malignant syndrome in a patient with Wilson’s disease. J Neurol Neurosurg Psychiatry 1988; 51: 1001–1002. PubMed PMC

Chroni E, Lekka NP, Tsibri E, et al. Acute progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson’s disease. J Neuropsychiatry Clin Neurosci 2001; 13: 531–532. PubMed

Svetel M, Pekmezovic T, Tomic A, et al. Quality of life in patients with treated and clinically stable Wilson’s disease. Mov Disord 2011; 26: 1503–1508. PubMed

Duggal HS, Nizamie H. Wilson’s disease presenting with obsessive-compulsive disorder. Indian J Psychiatry 2000; 42: 312–316. PubMed PMC

Ozcan O, Selimoglu MA. Self-injury in an adolescent with Wilson’s disease. Eur Child Adolesc Psychiatry 2009; 18: 761–762. PubMed

Lesniak M, Seniow J, Czlonkowska A. Abnormal antisaccades and smooth pursuit eye movements in patients with Wilson’s disease. Mov Disord 2008; 23: 2067–2073. PubMed

Keller R. Psychiatric symptoms as a late onset of Wilson’s disease: neuroradiological findings, clinical features and treatment. Ital J Neurol Sci 1999; 20: 49–54. PubMed

Squitti R, Bressi F, Pasqualetti P, et al. Longitudinal prognostic value of serum ‘free’ copper in patients with Alzheimer disease. Neurology 2009; 72: 50–55. PubMed

Lin JJ, Lin KL, Wang HS, et al. Psychological presentations without hepatic involvement in Wilson disease. Pediatr Neurol 2006; 35: 284–286. PubMed

Jackson GH, Meyer A, Lippmann S. Wilson’s disease: psychiatric manifestation may be the clinical presentation. Postgrad Med 1994; 95: 135–138. PubMed

Litwin T, Gromadzka G, Samochowiec J, et al. Association of dopamine receptor gene polymorphisms with the clinical course of Wilson disease. JIMD Rep 2013: 8: 73–80. PubMed PMC

Modai I, Karp L, Liberman UA, et al. Penicillamine therapy for schizophreniform psychosis in Wilson’s disease. J Nerv Ment Dis 1985; 173: 698–701. PubMed

Chen CL, Chen YS, Lui CC, et al. Neurological improvement of Wilson’s disease after liver transplantation. Transplant Proc 1997; 29: 497–498. PubMed

Bax RT, Hassler Luck W, et al. Cerebral manifestation of Wilson’s disease successfully treated with liver transplantation. Neurology 1998; 51: 863–865. PubMed

Sorbello O, Riccio D, Sini M, et al. Resolved psychosis after liver transplantation in a patient with Wilson’s disease. Clin Pract Epidemiol Ment Health 2011; 7: 182–184. PubMed PMC

Yagci MA, Tardu A, Karagul S, et al. Influence of liver transplantation on neuropsychiatric manifestations of Wilson disease. Transplant Proc 2015; 47: 1469–1473. PubMed

Medici V, Mirante VG, Fassati LR, et al. Liver transplantation for Wilson’s disease: the burden of neurological and psychiatric disorders. Liver Transpl 2005; 11: 1056–1063. PubMed

Guillaud O, Dumortier J, Sobesky R, et al. Long term results of liver transplantation for Wilson’s disease: experience in France. J Hepatol 2014; 60: 579–589. PubMed

Rich AM, Lajoie TM. Wilson’s disease: treatment of psychiatric manifestations in pregnancy. Psychosomatics 2012; 53: 175–177. PubMed

Chakor RT, Santhosh NS. Severe neuropsychiatric presentation of Wilson’s disease. Indian J Psychiatry 2011; 53: 170–171. PubMed PMC

Davis EJ, Borde M. Wilson’s disease and catatonia. Br J Psychiatry 1993; 162: 256–259. PubMed

Weiss KH, Askari FK, Czlonkowska A, et al. Bis-choline tetrathiomolybdate in patients with Wilson’s disease: an open-label, multicentre, phase 2 study. Lancet Gastroenetrol Hepatol 2017; 2: 869–876. PubMed

Neurologic impairment in Wilson disease

Wilson disease